Short answer
Tevogen Bio Holdings Inc. (TVGN) filed its Q3 2025 10-Q quarterly report on Nov 14, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$6M
- +2.7% YoY · −4.0% QoQ
- EPS (diluted)
- −$0.03
- −110.7% YoY · −50.0% QoQ
Source: XBRL data from the Tevogen Bio Holdings Inc. (TVGN) Q3 2025 10-Q on SEC EDGAR. USD.
Tevogen Bio Holdings Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Nasdaq non-compliance due to Common Stock closing bid below $1.00 for 30+ days as of Sept 23, 2025
- Material update: Nasdaq gives 180 days to regain $1.00 bid compliance, or risk delisting by March 23, 2026
- Regulatory risk: Potential Nasdaq delisting could impair stock liquidity and market price significantly
- Operational risk: High cash burn on TVGN 489 clinical, AI initiative, and other development programs requires substantial financing
- Financial risk: Convertible Preferred Stock, Loan and Sales Agreements may cause significant shareholder dilution and restrict financing flexibility
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tevogen Bio Holdings Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.